These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18215298)

  • 1. Ex Vivo Metrics, a preclinical tool in new drug development.
    Curtis CG; Bilyard K; Stephenson H
    J Transl Med; 2008 Jan; 6():5. PubMed ID: 18215298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 21st century drug development: advances, opportunities and challenges.
    Bhogal N
    Altern Lab Anim; 2009 Sep; 37(4):335-9. PubMed ID: 19807207
    [No Abstract]   [Full Text] [Related]  

  • 4. The future of drug safety testing: expanding the view and narrowing the focus.
    Stevens JL; Baker TK
    Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replicated, replicable and relevant-target engagement and pharmacological experimentation in the 21st century.
    Kenakin T; Bylund DB; Toews ML; Mullane K; Winquist RJ; Williams M
    Biochem Pharmacol; 2014 Jan; 87(1):64-77. PubMed ID: 24269285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of systems approaches on biological problems in drug discovery.
    Hood L; Perlmutter RM
    Nat Biotechnol; 2004 Oct; 22(10):1215-7. PubMed ID: 15470453
    [No Abstract]   [Full Text] [Related]  

  • 7. Prodrugs: Some thoughts and current issues.
    Stella VJ
    J Pharm Sci; 2010 Dec; 99(12):4755-65. PubMed ID: 20821387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From basic to clinical neuropharmacology: targetophilia or pharmacodynamics?
    Green AR; Aronson JK
    Br J Clin Pharmacol; 2012 Jun; 73(6):959-67. PubMed ID: 22360689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive assessment of ADMET risks in drug discovery.
    Wang J
    Curr Pharm Des; 2009; 15(19):2195-219. PubMed ID: 19601823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Requirements for a lead compound to become a clinical candidate.
    Hefti FF
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S7. PubMed ID: 19091004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
    Yang Y; Blomme EA; Waring JF
    Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cells in pharmaceutical biotechnology.
    Zuba-Surma EK; Józkowicz A; Dulak J
    Curr Pharm Biotechnol; 2011 Nov; 12(11):1760-73. PubMed ID: 21902635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods.
    Salade L; Wauthoz N; Goole J; Amighi K
    Int J Pharm; 2019 Apr; 561():47-65. PubMed ID: 30822505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New technologies in drug metabolism and toxicity screening: organ-to-organ interaction.
    Bhushan A; Martucci NJ; Usta OB; Yarmush ML
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):475-7. PubMed ID: 26940609
    [No Abstract]   [Full Text] [Related]  

  • 17. From in vivo to in vitro/in silico ADME: progress and challenges.
    Van de Waterbeemd H
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):1-4. PubMed ID: 16922647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De-risking drug discovery with ADDME -- avoiding drug development mistakes early.
    Tsaioun K; Jacewicz M
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():47-55. PubMed ID: 19807206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug delivery trends in clinical trials and translational medicine.
    Chien JY; Ho RJ
    J Pharm Sci; 2008 Jul; 97(7):2543-7. PubMed ID: 18512222
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.